4/A: SOPHiA GENETICS: Executive Equity Grant and Ownership Update

SOPHiA GENETICS SA files an amended Form 4 to correct previously reported beneficial ownership of ordinary shares and detail a new restricted stock unit grant and share option.

Summary

• This filing is an amendment to a previous Form 4, correcting the reported number of ordinary shares beneficially owned by Chief People Officer Manuela Valente.
• The corrected amount of ordinary shares beneficially owned is 224,248, an increase from the previously reported 71,869.
• A new grant of 71,869 Restricted Stock Units (RSUs) was awarded under the Issuer's 2021 Equity Incentive Plan.
• These RSUs vest over time: 25% on April 2, 2027, and the remainder quarterly through April 2, 2030.
• Additionally, a share option grant for 104,790 ordinary shares with an exercise price of $5.04 was granted.
• This share option vests 25% on April 2, 2027, and the remaining 75% in equal monthly installments through April 2, 2030, with an expiration date of April 2, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative correction and standard executive compensation disclosure, with no immediate positive or negative financial implications.

Positives

• Correction of beneficial ownership to a higher, more accurate figure indicates a potentially larger stake than initially reported.
• Grant of RSUs and share options signifies continued investment in and commitment from key management personnel.
• The vesting schedule for both RSUs and options is structured over several years, aligning executive incentives with long-term company performance.

Negatives

• The need for an amendment to correct a significant error in reporting beneficial ownership raises questions about internal controls and accuracy of prior disclosures.

Risks

• Potential for future dilution if a large number of options are exercised.
• Vesting schedules are subject to continued service, meaning departure from the company could result in forfeiture of unvested equity.

Future Outlook

The vesting schedules for the RSUs and share options extend through April 2, 2030, indicating a long-term incentive structure for the Chief People Officer.

Industry Context

StockSavvy.ai notes that equity grants to key personnel, such as Chief People Officers, are standard practice in the biotechnology and healthcare technology sectors to attract, retain, and incentivize talent, especially during periods of growth or restructuring.

Stakeholder Impact

• Shareholders: The correction in beneficial ownership may provide a more accurate picture of insider holdings. The equity grants are a standard form of compensation and are accounted for under existing plans.

Next Steps

• Continued service by Manuela Valente to meet vesting requirements for RSUs and share options.
• Monitoring of future equity transactions by management.

Key Dates

Keywords

SOPHiA GENETICS, Form 4, SEC Filing, Beneficial Ownership, Restricted Stock Units, RSU Grant, Share Options, Equity Incentive Plan, Manuela Valente, Chief People Officer, Stock Vesting